KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome from Non-Controlling InterestsIncome towards Parent CompanyNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRestructuring CostsRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Pfizer (PFE) EBT (2016 - 2025)

Pfizer (PFE) has disclosed EBT for 17 consecutive years, with -$1.6 billion as the latest value for Q4 2025.

  • On a quarterly basis, EBT fell 16320.0% to -$1.6 billion in Q4 2025 year-over-year; TTM through Dec 2025 was $13.3 billion, a 65.46% increase, with the full-year FY2025 number at $7.5 billion, down 6.27% from a year prior.
  • EBT was -$1.6 billion for Q4 2025 at Pfizer, down from $9.1 billion in the prior quarter.
  • In the past five years, EBT ranged from a high of $20.5 billion in Q4 2021 to a low of -$4.1 billion in Q4 2023.
  • A 5-year average of $4.7 billion and a median of $4.1 billion in 2024 define the central range for EBT.
  • Biggest YoY gain for EBT was 3055.34% in 2025; the steepest drop was 16320.0% in 2025.
  • Pfizer's EBT stood at $20.5 billion in 2021, then crashed by 56.06% to $9.0 billion in 2022, then crashed by 145.87% to -$4.1 billion in 2023, then soared by 99.76% to -$10.0 million in 2024, then tumbled by 16320.0% to -$1.6 billion in 2025.
  • Per Business Quant, the three most recent readings for PFE's EBT are -$1.6 billion (Q4 2025), $9.1 billion (Q3 2025), and $3.0 billion (Q2 2025).